Published in J Biol Chem on June 16, 2014
Alpha-synuclein function and dysfunction on cellular membranes. Exp Neurobiol (2014) 0.99
O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease. Nat Chem (2015) 0.94
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol (2015) 0.92
Systematic comparison of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS Genet (2014) 0.90
Mutations associated with familial Parkinson's disease alter the initiation and amplification steps of α-synuclein aggregation. Proc Natl Acad Sci U S A (2016) 0.85
The H50Q mutation induces a 10-fold decrease in the solubility of α-synuclein. J Biol Chem (2014) 0.84
The Interplay between Alpha-Synuclein Clearance and Spreading. Biomolecules (2015) 0.84
Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease. Proc Natl Acad Sci U S A (2016) 0.82
Alpha-synuclein Toxicity in the Early Secretory Pathway: How It Drives Neurodegeneration in Parkinsons Disease. Front Neurosci (2015) 0.80
Multiple system atrophy: genetic or epigenetic? Exp Neurobiol (2014) 0.80
Distinct clinical and neuropathological features of G51D SNCA mutation cases compared with SNCA duplication and H50Q mutation. Mol Neurodegener (2015) 0.79
Interactions between calcium and alpha-synuclein in neurodegeneration. Biomolecules (2014) 0.78
Bent out of shape: α-Synuclein misfolding and the convergence of pathogenic pathways in Parkinson's disease. FEBS Lett (2015) 0.78
Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity. Mol Neurodegener (2015) 0.78
Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant. PLoS One (2016) 0.77
Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease. Biomolecules (2015) 0.77
Role of neurotoxicants and traumatic brain injury in α-synuclein protein misfolding and aggregation. Brain Res Bull (2016) 0.76
Nanomolar oligomerization and selective co-aggregation of α-synuclein pathogenic mutants revealed by single-molecule fluorescence. Sci Rep (2016) 0.75
Copper(II) and the pathological H50Q α-synuclein mutant: Environment meets genetics. Commun Integr Biol (2017) 0.75
AFM-Based Single Molecule Techniques: Unraveling the Amyloid Pathogenic Species. Curr Pharm Des (2016) 0.75
Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism. F1000Res (2017) 0.75
α-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection. J Biol Chem (2017) 0.75
Genetic Variants in SNCA and the Risk of Sporadic Parkinson's Disease and Clinical Outcomes: A Review. Parkinsons Dis (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell (1977) 18.95
Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature (2006) 11.91
The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol (2004) 9.62
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A (2009) 6.87
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med (2008) 6.86
Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med (1998) 5.49
Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am J Pathol (1998) 5.47
A method for efficient isotopic labeling of recombinant proteins. J Biomol NMR (2001) 4.96
In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A (2011) 4.38
Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol (2001) 4.27
Intravesicular localization and exocytosis of alpha-synuclein and its aggregates. J Neurosci (2005) 3.93
Structure and dynamics of micelle-bound human alpha-synuclein. J Biol Chem (2004) 3.87
α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J Clin Invest (2011) 3.53
Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci U S A (2005) 3.48
Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Soc (2005) 3.13
Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem (2001) 3.13
A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins. J Mol Biol (2003) 2.97
Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation. J Biol Chem (1999) 2.86
The many faces of α-synuclein: from structure and toxicity to therapeutic target. Nat Rev Neurosci (2013) 2.78
A role for alpha-synuclein in the regulation of dopamine biosynthesis. J Neurosci (2002) 2.37
Binding of alpha-synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol Chem (1998) 2.32
Pre-fibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J (2009) 2.09
Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein. J Biol Chem (2008) 1.94
A general model for amyloid fibril assembly based on morphological studies using atomic force microscopy. Biophys J (2003) 1.93
Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J (2010) 1.90
A novel α-synuclein missense mutation in Parkinson disease. Neurology (2013) 1.74
Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem Biophys Res Commun (2008) 1.71
Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. Ann N Y Acad Sci (2008) 1.64
Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease. Mov Disord (2013) 1.64
Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res (2010) 1.57
Phosphorylation of synucleins by members of the Polo-like kinase family. J Biol Chem (2009) 1.57
Defective membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J Mol Biol (2002) 1.52
Residual structure, backbone dynamics, and interactions within the synuclein family. J Mol Biol (2007) 1.43
Helix periodicity, topology, and dynamics of membrane-associated alpha-synuclein. Protein Sci (2005) 1.41
Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death Differ (2007) 1.41
Mutant A53T alpha-synuclein induces neuronal death by increasing mitochondrial autophagy. J Biol Chem (2011) 1.33
Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J Neuropathol Exp Neurol (2008) 1.26
Modulation of receptor cycling by neuron-enriched endosomal protein of 21 kD. J Cell Biol (2002) 1.25
Polo-like kinase 2 regulates selective autophagic α-synuclein clearance and suppresses its toxicity in vivo. Proc Natl Acad Sci U S A (2013) 1.24
Cell-produced alpha-synuclein oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging (2008) 1.23
Coordination features and affinity of the Cu²+ site in the α-synuclein protein of Parkinson's disease. Biochemistry (2011) 1.20
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet (2000) 1.17
Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers. Exp Mol Med (2011) 1.12
Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem (2001) 1.12
The Parkinson's disease-associated H50Q mutation accelerates α-Synuclein aggregation in vitro. Biochemistry (2013) 1.08
Elucidating the role of C-terminal post-translational modifications using protein semisynthesis strategies: α-synuclein phosphorylation at tyrosine 125. J Am Chem Soc (2012) 1.06
E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein. J Mol Biol (2009) 1.05
The alpha-synuclein mutation E46K promotes aggregation in cultured cells. Exp Neurol (2005) 1.04
NMR mapping of copper binding sites in alpha-synuclein. Biochim Biophys Acta (2005) 1.01
α-Synuclein mutations cluster around a putative protein loop. Neurosci Lett (2013) 1.00
Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease. J Neurosci (2012) 0.99
A novel mechanism of interaction between alpha-synuclein and biological membranes. J Mol Biol (2006) 0.96
The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells. Hum Mol Genet (2014) 0.95
Somatic alpha-synuclein mutations in Parkinson's disease: hypothesis and preliminary data. Mov Disord (2013) 0.94
Phosphorylation of α-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane binding property in Caenorhabditis elegans. J Biol Chem (2012) 0.91
Differential regulation of wild-type and mutant alpha-synuclein binding to synaptic membranes by cytosolic factors. BMC Neurosci (2008) 0.91
In vitro study of α-synuclein protofibrils by cryo-EM suggests a Cu(2+)-dependent aggregation pathway. Biophys J (2013) 0.90
Extracellular signal-regulated kinase is involved in alpha-synuclein-induced mitochondrial dynamic disorders by regulating dynamin-like protein 1. Neurobiol Aging (2012) 0.89
Copper(II) binding by fragments of alpha-synuclein containing M1-D2- and -H50-residues; a combined potentiometric and spectroscopic study. Dalton Trans (2006) 0.86